GSK Vaccines: Injecting Visibility
Executive Summary
A broad vaccines portfolio, a blockbuster asset swap with Novartis, and an R&D revamp including significant, long-term investment in technology platforms have cemented GlaxoSmithKline’s leadership in a perennially lucrative business that is core to its corporate ethos. Why hasn’t anyone seemed to notice?
You may also be interested in...
GSK US Pharma President Jack Bailey On A “Dynamic” 2017
With new US President Trump in place, new corporate CEO Walmsley to take the reins in April and the opportunity for four US drug launches in 2017, GSK’s president of US Pharmaceuticals says he is preparing for an “intense” year.
To Outperform In Pharma, Go Deep – Not Broad
The world’s most successful pharma companies aren’t winning on the basis of absolute scale; they succeed instead thanks to their leadership in a few clearly defined product categories. That approach delivers outsized returns, while helping firms navigate a changing health care landscape where payers and providers increasingly demand evidence of treatment efficacy.
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.